Enveric Biosciences Inc vs FuelCell Energy Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while FuelCell Energy Inc trades at $19.42 (market cap $1.59B). The key difference: FuelCell Energy Inc is far larger — about 256.5× Enveric Biosciences Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | FCEL | |
|---|---|---|
Market Cap | $6.20M | $1.59B |
Sector | Health | Industrials |
52-Week High | $17.40 | $36.01 |
52-Week Low | $1.27 | $3.92 |
Enterprise Value | $1.30M | $1.43B |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
FCEL trades at $20.43, up 0.54% today, near the analyst consensus target of $20.75. The stock shows a bearish technical signal with negative moving averages, while fundamentals reveal persistent losses: revenue grew to $158.16M in 2025 but net income margin was -132.41%. Recent news highlights partnerships with Siemens and AI data center demand as growth catalysts, though cash flow from operations remains negative at -$125.29M.
FCEL presents high-risk growth potential driven by alternative energy tailwinds and strategic alliances, but investment is speculative due to unprofitability, cash burn, and competitive pressures. Analysts are split evenly between Buy and Hold ratings, reflecting cautious optimism amid financial challenges. The stock's outlook hinges on execution toward profitability and scaling commercial projects.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →